Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Exercise  COVID-19 treatment studies for Exercise  C19 studies: Exercise  Exercise   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Severe case 47% unadjusted Improvement Relative Risk Severe case (b) 8% unadjusted Case 66% c19early.com/ex Huang et al. Exercise for COVID-19 Prophylaxis Favors exercise Favors inactivity
Huang, 164 patient exercise study: 47% lower severe cases [p=0.18] and 66% fewer cases [p=0.004] https://c19p.org/huang5
copied to clipboard
Reduced Sleep in the Week Prior to Diagnosis of COVID-19 is Associated with the Severity of COVID-19
Huang et al., Nature and Science of Sleep, doi:10.2147/NSS.S263488
30 Nov 2021    Source   PDF   Share   Tweet
Retrospective 164 COVID-19 patients and 188 controls in China, showing lower risk of cases with regular exercise.
risk of severe case, 46.8% lower, RR 0.53, p = 0.18, high activity levels 7 of 74 (9.5%), low activity levels 16 of 90 (17.8%), NNT 12, unadjusted, exercise habit, ≥1 time per week, excluded in exclusion analyses: unadjusted results with no group details.
risk of severe case, 8.0% lower, RR 0.92, p = 1.00, high activity levels 3 of 23 (13.0%), low activity levels 20 of 141 (14.2%), NNT 88, unadjusted, ≥30 minutes ≥3 times per week, excluded in exclusion analyses: unadjusted results with no group details.
risk of case, 65.9% lower, OR 0.34, p = 0.004, adjusted per study, case control OR, regular exercise, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Huang et al., 11/30/2021, retrospective, China, Asia, peer-reviewed, survey, 5 authors, study period 10 February, 2020 - 28 March, 2020.
Contact: lidiangeng@126.com, bao03@163.com.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit